Pancreatic cancer screening in a clinical practice setting: it is the moment of Prevention

Authors

DOI:

https://doi.org/10.47892/rgp.2022.424.1373

Keywords:

Pancreatic Neoplasms, Surveillance, Endosonography, Magnetic Resonance Spectroscopy

Abstract

Pancreatic cancer surveillance can improve outcomes in high-risk individuals. However, little is known about its applicability and findings in routine clinical practice. Our aim was to evaluate findings on screening tests in high-risk individuals in a clinical practice setting and to analyze factors associated with the presence of relevant pancreatic lesions. We developed a prospective observational study of pancreatic cancer high risk patients that meet criteria of surveillance from the International Cancer of the Pancreas Screening Consortium. The demographic variables, other risk factors and imaging findings are collected. Patients with significant findings are compared to those without noteworthy findings. Of 70 high-risk individuals, 25 fitted the criteria for pancreatic cancer surveillance. The most frequent condition was hereditary breast and ovarian cancer syndrome (60%). We identified eleven abnormal imaging findings (44%) and three of them (12%) were relevant: two intraductal papillary mucinous neoplasms and one localized pancreatic neoplasm. BRCA2 mutation was more frequent in patients with significant lesions (66.7% vs 30%, p=0.376) but smoking and diabetes were not associated with relevant findings (0 vs 18 %, p=0.578 and 0 vs 4.5%, p=0.880 respectively). Screening test could detect early-stage or resectable lesions in a significant in a significant percentage of the selected ings were in patients belonging to hereditary breast and ovarian cancer syndrome.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Author Biography

Luisa Adán-Merino, Servicio de Aparato Digestivo. Hospital Universitario Infanta Leonor. Madrid, España.

Médico Especialista en Aparato Digestivo

Profesora Asociada Universidad Complutense Madrid

References

Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913-21.

Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371(11):1039-49.

Huang J, Lok V, Ngai CH, Zhang L, Yuan J, Lao XQ, et al. Worldwide Burden of, Risk Factors for, and Trends in Pancreatic Cancer. Gastroenterology. 2021;160(3):744-54.

Singhi AD, Koay EJ, Chari ST, Maitra A. Early Detection of Pancreatic Cancer: Opportunities and Challenges. Gastroenterology. 2019;156(7):2024-40.

Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley JW, Kamel I, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013;62(3):339-47.

Goggins M, Overbeek KA, Brand R, Syngal S, Del Chiaro M, Bartsch DK, et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut. 2020;69(1):7-17.

Signoretti M, Bruno MJ, Zerboni G, Poley JW, Delle Fave G, Capurso G. Results of surveillance in individuals at high‐risk of pancreatic cancer: A systematic review and meta‐analysis. United Eur Gastroenterol J. 2018;6(4):489-99.

Paiella S, Salvia R, De Pastena M, Pollini T, Casetti L, Landoni L, et al. Screening/surveillance programs for pancreatic cancer in familial high-risk individuals: A systematic review and proportion meta-analysis of screening results. Pancreatol Off J Int Assoc Pancreatol IAP Al. 2018;18(4):420-8.

Corral JE, Mareth KF, Riegert-Johnson DL, Das A, Wallace MB. Diagnostic Yield From Screening Asymptomatic Individuals at High Risk for Pancreatic Cancer: A Meta-analysis of Cohort Studies. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2019;17(1):41-53.

Paiella S, Capurso G, Cavestro GM, Butturini G, Pezzilli R, Salvia R, et al. Results of First-Round of Surveillance in Individuals at High-Risk of Pancreatic Cancer from the AISP (Italian Association for the Study of the Pancreas) Registry. Am J Gastroenterol. 2019;114(4):665-70.

Brune K, Abe T, Canto M, O’Malley L, Klein AP, Maitra A, et al. Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol. 2006;30(9):1067-76.

Henrikson NB, Aiello Bowles EJ, Blasi PR, Morrison CC, Nguyen M, Pillarisetty VG, et al. Screening for Pancreatic Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2019;322(5):445.

van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, Hoogerbrugge N, Verhoef S, Vasen HFA, et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet. 2005;42(9):711-9.

Aslanian HR, Lee JH, Canto MI. AGA Clinical Practice Update on Pancreas Cancer Screening in High-Risk Individuals: Expert Review. Gastroenterology. 2020;159(1):358-62.

Stoffel EM, McKernin SE, Brand R, Canto M, Goggins M, Moravek C, et al. Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37(2):153-64.

National Comprehensive Cancer Network (NCCN) guidelines (v1.2020); available online at https://www.nccn.org/professionals/physician_gls.

Brentnall TA, Bronner MP, Byrd DR, Haggitt RC, Kimmey MB. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med. 1999;131(4):247-55.

Del Chiaro M, Verbeke CS, Kartalis N, Pozzi Mucelli R, Gustafsson P, Hansson J, et al. Short-term Results of a Magnetic Resonance Imaging-Based Swedish Screening Program for Individuals at Risk for Pancreatic Cancer. JAMA 2015;150(6):512-8.

Sud A, Wham D, Catalano M, Guda NM. Promising outcomes of screening for pancreatic cancer by genetic testing and endoscopic ultrasound. Pancreas. 2014;43(3):458-61.

Canto MI, Goggins M, Yeo CJ, Griffin C, Axilbund JE, Brune K, et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2004;2(7):606-21.

Published

01/25/2023

How to Cite

1.
Adán-Merino L, Mora-Soler A, Zaera-De la Fuente C, Garrido-Gallego F, Crivillén-Anguita O, Ponferrada-Díaz Ángel. Pancreatic cancer screening in a clinical practice setting: it is the moment of Prevention. Rev Gastroenterol Peru [nternet]. 2023 Jan. 25 [cited 2024 Dec. 21];42(4):234-41. vailable from: https://revistagastroperu.com/index.php/rgp/article/view/1373

Issue

Section

ARTÍCULOS ORIGINALES